http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Aguilar-Calderón (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Effects of nonlinear friction compensation in the inertia wheel pendulum
Carlos Aguilar-Avelar,Ricardo Rodríguez-Calderón,Sergio Puga-Guzmán,Javier Moreno-Valenzuela 대한기계학회 2017 JOURNAL OF MECHANICAL SCIENCE AND TECHNOLOGY Vol.31 No.9
This paper discusses for the first time the effects of modeling, identifying and compensating nonlinear friction for the control of the inertia wheel pendulum and proposes a new algorithm for the stabilization of the pendulum at the upward unstable position. First, it is shown that the dynamic model with the proposed asymmetric Coulomb friction component characterizes better the real experimental platform of the system. Then, a feedback linearization based controller with friction compensation was designed, where theoretical results show the stability of the output trajectories. Finally, the new algorithm was experimentally compared with its version without friction compensation, showing that the new scheme yields better performance with less power consumption.
-
Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
José Carlos Jaime-Pérez,Patrizia Aguilar-Calderón,Lorena Salazar-Cavazos,Andrés Gómez-De León,David Gómez-Almaguer 대한혈액학회 2019 Blood Research Vol.54 No.2
BackgroundWarm autoimmune hemolytic anemia (w-AIHA) is an uncommon disease with heteroge-neous response to treatment. Steroids are the standard treatment at diagnosis, whereas rituximab has recently been recommended as the second-line therapy of choice. Our main objective was to document the response to treatment in patients with newly diag-nosed w-AIHA, including the effectiveness of low-dose rituximab as frontline treatment and for refractory disease.MethodsPatients with w-AIHA from 2002 to 2017 were included. Relapse-free survival (RFS), prob-ability of maintained response (MR), and time-to-response were analyzed using the Kaplan‒Meier method. Response was classified as complete, partial, and no response.ResultsWe included 64 adults with w-AIHA (39 women and 25 men). The median age was 37 (16‒77) years. Response rates to steroids alone were 76.7%, rituximab plus steroids, 100%; and cyclophosphamide, 80%. RFS with steroids at 6, 36, and 72 months was 86.3%, 65.1%, and 59.7%, respectively. Eighteen patients received rituximab at 100 mg/wk for 4 weeks plus high-dose dexamethasone as first-line therapy, with RFS at 6, 36, and 72 months of 92.3%, 58.7% and 44.1%, respectively. Eight patients refractory to several lines of therapy were treated with low-dose rituximab, and all achieved a response (three com-plete response and five partial response) at a median 16 days (95% confidence interval, 14.1‒17.8), with a 75% probability of MR at 103 months; the mean MR was 81.93±18months.ConclusionOutcomes of w-AIHA treatment were considerably heterogeneous. Low rituximab doses plus high dexamethasone doses were effective for refractory disease.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
